The DNB//Back Bay Partnership’s #MarketUpdate report for the week ending November 22nd is now available. Highlights include: ➡️ US indices ended the week with minor gains, largely driven by Nvidia’s strong Q3 earnings ➡️ Licensing deals had one of their busiest weeks in Q4 so far with five deals announced, each with a potential aggregate deal value of $500M or more ⏹️ The largest deal was Kyowa Kirin, Inc.- U.S., paying $330M upfront and pledging up to $933M in milestones to split the US profits of Kura Oncology, Inc.’s Phase 2 oral leukemia treatment, in addition to obtaining commercialization rights for the rest of the world ⏹️ Radiopharmaceuticals continues to be one of the hottest modalities within oncology deals this year as Novartis added another program to its pipeline, penning a research collaboration deal worth up to $745M for the rights of an SSTR2-targeting asset from Ratio Therapeutics ➡️ Novartis made headlines with its $1.1B structured acquisition of Kate Therapeutics, providing the Swiss drug maker with gene therapy preclinical programs targeting Duchenne muscular dystrophy (DMD), facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1) Read the full update here: https://bit.ly/3AX7ob2 #radiopharmaceuticals #oncology #healthcaremarket #investmentbanking #corporatebanking #marketsinc #markettrends #financing #BBLSA #DNB
